Top Markets
#1 MowCat MowCat +49.05%
#2 Velvet Velvet +36.37%
#3 Audiera Audiera +22.76%
#4 Derive Derive +20.53%
#5 Bermuda Shorts Bermuda Shorts +18.78%
#6 Quack AI Quack AI +18.60%
#7 MarsCoin MarsCoin +16.83%
#8 aPriori aPriori +15.97%
#9 Biconomy Biconomy +13.11%
#10 Cross Cross +11.62%
Coin of the day
MowCat MowCat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
Kedudukan dalam Saham #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Harga Saham
$2.37
Disegerakkan terakhir: 2025-12-15
Modal Pasaran
$3.99M
Perubahan (1 hari)
-5.58%
Perubahan (1 tahun)
24.74%
Negara
US
Perdagangan Qualigen Therapeutics, Inc. (QLGN)

Kategori

Healthcare
Pendapatan untuk Qualigen Therapeutics, Inc. (QLGN)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Qualigen Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Qualigen Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE